Skip to main content
HR 2700 108th Congress House Health Access to health care Ambulatory care Congress Congressional reporting requirements Cost accounting Drugs Governmental investigations Hemophilia Hospital rates Medicare Orphan drugs Overhead costs Pharmacies Social Welfare

Medicare Patient Access to Drugs for Rare Diseases Act of 2003

Introduced: July 10, 2003 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 108th Congress ended
It never became law before the 108th Congress (2003–2004) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 23, 2003
Referred to the Subcommittee on Health.
Jul 22, 2003
Referred to the Subcommittee on Health.
Jul 10, 2003
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 10, 2003
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medicare Patient Access to Drugs for Rare Diseases Act of 2003 - Amends title XVIII (Medicare) of the Social Security Act to revise the methodology by which payment for orphan drugs and biologicals is made under the Medicare prospective payment system for hospital outpatient department (OPD) services.

Directs the Secretary to report to specified congressional committees on payment for orphan drugs and biologicals and blood clotting factors for individuals with hemophilia in the OPD setting, including recommendations for either continuing or discontinuing the exclusion of such drugs and biologicals from payment under Medicare.

Provides for a moratorium on decreases in payment rates for orphan drugs and biologicals and blood clotting factors for certain individuals with hemophilia.

What's happening now July 23, 2003

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 5
All 5 Democratic 3 Republican 2
D
Sánchez, Linda T.
California · Feb 24, 2004
 D
Lynch, Stephen F.
Massachusetts · Oct 17, 2003
 R
Calvert, Ken
California · Sep 23, 2003
 D
Pallone, Frank
New Jersey · Sep 23, 2003
 R
Issa, Darrell
California · Jul 10, 2003
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2700: Medicare Patient Access to Drugs for Rare Diseases Act of 2003. 108th Congress. Open America. https://openamerica.io/bill/108-HR-2700/
MLA
"H.R. 2700: Medicare Patient Access to Drugs for Rare Diseases Act of 2003." 108th Congress, 2026, Open America, https://openamerica.io/bill/108-HR-2700/.
Bluebook (legal)
H.R. 2700, 108th Cong. (2026), https://openamerica.io/bill/108-HR-2700/.
Markdown link
[H.R. 2700: Medicare Patient Access to Drugs for Rare Diseases Act of 2003](https://openamerica.io/bill/108-HR-2700/)
Report a problem